<!DOCTYPE html>
<html lang="en" class="dark">
<head>
  <meta charset="UTF-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0" />
  <title>Licensing Opportunities | MDC Platform</title>
  <script src="https://cdn.tailwindcss.com"></script>
</head>
<body class="bg-gray-950 text-gray-200 font-mono">
  <header class="p-6 text-center border-b border-gray-800">
    <h1 class="text-3xl font-bold text-white">Licensing Opportunities</h1>
    <p class="text-gray-400 mt-2 max-w-3xl mx-auto">
      MDC innovations are available for exclusive or non-exclusive licensing across therapeutic domains. Select a compound, review its summary, and submit an interest form to initiate discussion.
    </p>
  </header>

  <section class="p-6 max-w-5xl mx-auto space-y-10">
    <div class="grid md:grid-cols-2 gap-6">
      <div class="bg-gray-900 p-6 rounded-lg border border-gray-800 hover:border-green-500 transition">
        <h2 class="text-xl font-semibold text-white">Zn²⁺-Ivermectin (Antiviral)</h2>
        <p class="text-gray-400 mt-2">Optimized for enhanced viral protein affinity and oral bioavailability. Preclinical insights support potential in respiratory and cytoplasmic-targeted viruses.</p>
        <a href="licensing-form.html?compound=Zn²⁺-Ivermectin" class="inline-block mt-4 text-green-400 underline">Submit Licensing Interest</a>
      </div>

      <div class="bg-gray-900 p-6 rounded-lg border border-gray-800 hover:border-green-500 transition">
        <h2 class="text-xl font-semibold text-white">Cu²⁺-Histidine (Neuroinflammation)</h2>
        <p class="text-gray-400 mt-2">ROS-responsive agent with anti-inflammatory properties and metal-assisted delivery timing. Target: oxidative stress conditions in neurodegenerative pathways.</p>
        <a href="licensing-form.html?compound=Cu²⁺-Histidine" class="inline-block mt-4 text-green-400 underline">Submit Licensing Interest</a>
      </div>

      <div class="bg-gray-900 p-6 rounded-lg border border-gray-800 hover:border-green-500 transition">
        <h2 class="text-xl font-semibold text-white">Ru⁴⁺-Doxorubicin (Oncology)</h2>
        <p class="text-gray-400 mt-2">Designed for selective tumor activation in acidic microenvironments. Enables logic-gated toxicity with metal-mediated stability.</p>
        <a href="licensing-form.html?compound=Ru⁴⁺-Doxorubicin" class="inline-block mt-4 text-green-400 underline">Submit Licensing Interest</a>
      </div>

      <div class="bg-gray-900 p-6 rounded-lg border border-gray-800 hover:border-green-500 transition">
        <h2 class="text-xl font-semibold text-white">Bi³⁺-Minocycline (Spinal/CNS Repair)</h2>
        <p class="text-gray-400 mt-2">MDC for neuroprotection, axonal regeneration, and trauma-targeted delivery. Currently under evaluation for spinal cord injury support.</p>
        <a href="licensing-form.html?compound=Bi³⁺-Minocycline" class="inline-block mt-4 text-green-400 underline">Submit Licensing Interest</a>
      </div>
    </div>

    <div class="text-center mt-10">
      <a href="index.html" class="text-sm text-blue-400 underline">&larr; Back to MDC Home/index</a>
    </div>
  </section>

  <footer class="text-center p-6 border-t border-gray-800 text-gray-600 text-sm mt-10">
    &copy; 2025 Kunfirm Technologies. Licensing managed by MDC Platform under KT Biotech. Submissions are confidential.
  </footer>
</body>
</html>
